Presentation is loading. Please wait.

Presentation is loading. Please wait.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Published byΙόλη Μεσσηνέζης Modified over 5 years ago

Similar presentations

Presentation on theme: "Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension."— Presentation transcript:

1 Risk assessment and treat-to-target approach for pulmonary arterial hypertension.
Risk assessment and treat-to-target approach for pulmonary arterial hypertension. WHO-FC: World Health Organization-functional class; 6MWD: 6-min walking distance; CPET: cardiopulmonary exercise testing; Echo: echocardiography; BNP: brain natriuretic peptide; NT-proBNP: N-terminal-pro-brain natriuretic peptide. Adapted from [15] with permission from the publisher. Lewis J. Rubin et al. Eur Respir Rev 2012;21: ©2012 by European Respiratory Society

Download ppt "Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension."

Similar presentations

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado
Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Editorial Heart Failure Clinics

Editorial Heart Failure Clinics
Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.

Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.
Cohort identification and exclusion.

Cohort identification and exclusion.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
REVEAL pulmonary arterial hypertension (PAH) risk score.

REVEAL pulmonary arterial hypertension (PAH) risk score.
Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,
Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.

Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.
An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.
An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.

An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.
Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.
Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.
Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)
Micha T. Maeder, MD, PhD, Niklas F. Ehl, MD 

Micha T. Maeder, MD, PhD, Niklas F. Ehl, MD 

Similar presentations

Ads by Google